171 related articles for article (PubMed ID: 8031871)
1. Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method.
Li M; Meares CF; Zhong GR; Miers L; Xiong CY; DeNardo SJ
Bioconjug Chem; 1994; 5(2):101-4. PubMed ID: 8031871
[TBL] [Abstract][Full Text] [Related]
2. Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.
Li M; Meares CF; Salako Q; Kukis DL; Zhong GR; Miers L; DeNardo SJ
Cancer Res; 1995 Dec; 55(23 Suppl):5726s-5728s. PubMed ID: 7493335
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
DeNardo SJ; Zhong GR; Salako Q; Li M; DeNardo GL; Meares CF
J Nucl Med; 1995 May; 36(5):829-36. PubMed ID: 7738660
[TBL] [Abstract][Full Text] [Related]
5. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates.
Gansow OA
Int J Rad Appl Instrum B; 1991; 18(4):369-81. PubMed ID: 1864725
[TBL] [Abstract][Full Text] [Related]
6. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
Lewis MR; Raubitschek A; Shively JE
Bioconjug Chem; 1994; 5(6):565-76. PubMed ID: 7873659
[TBL] [Abstract][Full Text] [Related]
7. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
[TBL] [Abstract][Full Text] [Related]
9. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent.
Deshpande SV; DeNardo SJ; Kukis DL; Moi MK; McCall MJ; DeNardo GL; Meares CF
J Nucl Med; 1990 Apr; 31(4):473-9. PubMed ID: 2324823
[TBL] [Abstract][Full Text] [Related]
10. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
[TBL] [Abstract][Full Text] [Related]
11. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy.
Pnwar P; Iznaga-Escobar N; Mishra P; Srivastava V; Sharma RK; Chandra R; Mishra AK
Cancer Biol Ther; 2005 Aug; 4(8):854-60. PubMed ID: 16082184
[TBL] [Abstract][Full Text] [Related]
12. Regressive DOTA labelling performance with indium-111 and yttrium-90 over a week of use.
Hainsworth JE; Mather SJ
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1348. PubMed ID: 16142470
[No Abstract] [Full Text] [Related]
13. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
Kukis DL; DeNardo SJ; DeNardo GL; O'Donnell RT; Meares CF
J Nucl Med; 1998 Dec; 39(12):2105-10. PubMed ID: 9867151
[TBL] [Abstract][Full Text] [Related]
14. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions.
Lewis MR; Shively JE
Bioconjug Chem; 1998; 9(1):72-86. PubMed ID: 9460549
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW
Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971
[TBL] [Abstract][Full Text] [Related]
16. Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes.
Sosabowski JK; Mather SJ
Nat Protoc; 2006; 1(2):972-6. PubMed ID: 17406332
[TBL] [Abstract][Full Text] [Related]
17. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
[TBL] [Abstract][Full Text] [Related]
18. Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl- or amino-directed coupling to antibodies. Conjugates retain immunoreactivity and have similar biodistributions.
Li L; Tsai SW; Anderson AL; Keire DA; Raubitschek AA; Shively JE
Bioconjug Chem; 2002; 13(1):110-5. PubMed ID: 11792185
[TBL] [Abstract][Full Text] [Related]
19. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA).
Camera L; Kinuya S; Garmestani K; Brechbiel MW; Wu C; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
Eur J Nucl Med; 1994 Jul; 21(7):640-6. PubMed ID: 7957350
[TBL] [Abstract][Full Text] [Related]
20. Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1,4,8,11-tetraazacyclotetradec-1-yl)methyl]benzoic acid.
Smith-Jones PM; Fridrich R; Kaden TA; Novak-Hofer I; Siebold K; Tschudin D; Maecke HR
Bioconjug Chem; 1991; 2(6):415-21. PubMed ID: 1805938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]